PE20050769A1 - Formas polimorficas de un agonista de gabaa - Google Patents
Formas polimorficas de un agonista de gabaaInfo
- Publication number
- PE20050769A1 PE20050769A1 PE2005000102A PE2005000102A PE20050769A1 PE 20050769 A1 PE20050769 A1 PE 20050769A1 PE 2005000102 A PE2005000102 A PE 2005000102A PE 2005000102 A PE2005000102 A PE 2005000102A PE 20050769 A1 PE20050769 A1 PE 20050769A1
- Authority
- PE
- Peru
- Prior art keywords
- polymorphic forms
- gaboxadol
- refers
- crystal form
- gabaa agonist
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 abstract 4
- 229950004346 gaboxadol Drugs 0.000 abstract 2
- UDHPXYNRXFPDOF-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrate Chemical compound O.C1NCCC2=C1ON=C2O UDHPXYNRXFPDOF-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402118.4A GB0402118D0 (en) | 2004-01-30 | 2004-01-30 | Polymorphic forms of a GABAA agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050769A1 true PE20050769A1 (es) | 2005-10-04 |
Family
ID=31971783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000102A PE20050769A1 (es) | 2004-01-30 | 2005-01-27 | Formas polimorficas de un agonista de gabaa |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7262300B2 (https=) |
| EP (2) | EP2042505A1 (https=) |
| JP (1) | JP4917440B2 (https=) |
| KR (1) | KR101210361B1 (https=) |
| CN (1) | CN1914212B (https=) |
| AR (1) | AR047511A1 (https=) |
| AT (1) | ATE414088T1 (https=) |
| AU (1) | AU2005209473B2 (https=) |
| BR (1) | BRPI0506858A (https=) |
| CA (1) | CA2554536C (https=) |
| CO (1) | CO5700743A2 (https=) |
| CY (1) | CY1108647T1 (https=) |
| DE (1) | DE602005010975D1 (https=) |
| DK (1) | DK1713813T3 (https=) |
| DO (1) | DOP2005000013A (https=) |
| EA (1) | EA009413B1 (https=) |
| EC (1) | ECSP066735A (https=) |
| ES (1) | ES2314613T3 (https=) |
| GB (2) | GB0402118D0 (https=) |
| HR (1) | HRP20080614T3 (https=) |
| IL (1) | IL176863A0 (https=) |
| MA (1) | MA28364A1 (https=) |
| MX (1) | MXPA06008595A (https=) |
| MY (1) | MY139525A (https=) |
| NO (1) | NO20063843L (https=) |
| NZ (1) | NZ548191A (https=) |
| PE (1) | PE20050769A1 (https=) |
| PL (1) | PL1713813T3 (https=) |
| PT (1) | PT1713813E (https=) |
| SI (1) | SI1713813T1 (https=) |
| TW (1) | TWI345972B (https=) |
| UA (1) | UA87487C2 (https=) |
| WO (1) | WO2005073237A2 (https=) |
| ZA (1) | ZA200605307B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| DE102005004343A1 (de) * | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
| EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPH SHAPES OF A GABAA AGONIST |
| KR101271263B1 (ko) | 2005-09-28 | 2013-06-07 | 아우리스 메디칼 아게 | 내이 장애 치료용 약학 조성물 |
| CN102093387B (zh) * | 2009-12-10 | 2012-07-25 | 天津泰普医药知识产权流转储备中心有限公司 | 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物 |
| WO2013087090A1 (en) | 2011-12-12 | 2013-06-20 | Auris Medical Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
| EP4541420A3 (en) | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| EP3481387A4 (en) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
| CN110225754A (zh) * | 2016-11-22 | 2019-09-10 | 奥维德医疗公司 | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| JP2020529440A (ja) | 2017-08-04 | 2020-10-08 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
| WO2020061410A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
| JP2022514194A (ja) | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
| WO2020131856A1 (en) | 2018-12-17 | 2020-06-25 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
| US11364228B2 (en) | 2019-12-18 | 2022-06-21 | Ovid Therapeutics Inc. | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| US4315934A (en) | 1979-09-24 | 1982-02-16 | Sandoz Ltd. | Organic compounds |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4352731A (en) * | 1980-11-03 | 1982-10-05 | Occidental Research Corporation | Apparatus for selective wetting of particles |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| UA52661C2 (uk) * | 1996-06-14 | 2003-01-15 | Ново Нордіск А/С | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти |
| EP1220658A1 (en) | 1999-09-28 | 2002-07-10 | H. Lundbeck A/S | Melt granulated composition and modified release dosage form prepared from said composition |
| AR031473A1 (es) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| BR0209820A (pt) | 2001-05-18 | 2004-06-01 | Lonza Ag | Processo para a preparação de formulações sólidas de 3-hidróxi-3-metilbutirato de sódio |
| AU2002338855B2 (en) | 2001-05-21 | 2007-08-16 | H. Lundbeck A/S | Granular preparations of gaboxadol |
| WO2004022550A1 (en) * | 2002-09-03 | 2004-03-18 | Naturon Limited | Compound for treatment of anxiety and methods of preparation and use thereof |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| BRPI0410857A (pt) * | 2003-06-25 | 2006-07-04 | Lundbeck & Co As H | método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica |
| AR045540A1 (es) * | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
| US20070032553A1 (en) | 2003-09-10 | 2007-02-08 | Mckernan Ruth | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| TW200528098A (en) | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| MXPA06015196A (es) | 2004-06-29 | 2007-03-15 | Lundbeck & Co As H | Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide. |
| GB0417558D0 (en) | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPH SHAPES OF A GABAA AGONIST |
| WO2006102093A1 (en) | 2005-03-18 | 2006-09-28 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| US20080262029A1 (en) | 2005-04-29 | 2008-10-23 | H. Lundbeck A/S | Acid and Base Salt Forms of Gaboxadol |
-
2004
- 2004-01-30 GB GBGB0402118.4A patent/GB0402118D0/en not_active Ceased
-
2005
- 2005-01-20 AR ARP050100210A patent/AR047511A1/es not_active Application Discontinuation
- 2005-01-21 TW TW094101857A patent/TWI345972B/zh not_active IP Right Cessation
- 2005-01-24 MY MYPI20050253A patent/MY139525A/en unknown
- 2005-01-27 PE PE2005000102A patent/PE20050769A1/es not_active Application Discontinuation
- 2005-01-28 DO DO2005000013A patent/DOP2005000013A/es unknown
- 2005-01-28 PT PT05702040T patent/PT1713813E/pt unknown
- 2005-01-28 DE DE602005010975T patent/DE602005010975D1/de not_active Expired - Lifetime
- 2005-01-28 US US11/045,768 patent/US7262300B2/en not_active Expired - Lifetime
- 2005-01-28 NZ NZ548191A patent/NZ548191A/en not_active IP Right Cessation
- 2005-01-28 EP EP08019457A patent/EP2042505A1/en not_active Withdrawn
- 2005-01-28 ES ES05702040T patent/ES2314613T3/es not_active Expired - Lifetime
- 2005-01-28 JP JP2006550301A patent/JP4917440B2/ja not_active Expired - Lifetime
- 2005-01-28 PL PL05702040T patent/PL1713813T3/pl unknown
- 2005-01-28 UA UAA200609410A patent/UA87487C2/ru unknown
- 2005-01-28 MX MXPA06008595A patent/MXPA06008595A/es active IP Right Grant
- 2005-01-28 EA EA200601404A patent/EA009413B1/ru not_active IP Right Cessation
- 2005-01-28 DK DK05702040T patent/DK1713813T3/da active
- 2005-01-28 GB GB0501847A patent/GB2410434A/en not_active Withdrawn
- 2005-01-28 CA CA2554536A patent/CA2554536C/en not_active Expired - Fee Related
- 2005-01-28 AT AT05702040T patent/ATE414088T1/de active
- 2005-01-28 SI SI200530521T patent/SI1713813T1/sl unknown
- 2005-01-28 CN CN2005800031615A patent/CN1914212B/zh not_active Expired - Lifetime
- 2005-01-28 HR HR20080614T patent/HRP20080614T3/xx unknown
- 2005-01-28 AU AU2005209473A patent/AU2005209473B2/en not_active Ceased
- 2005-01-28 BR BRPI0506858-4A patent/BRPI0506858A/pt not_active IP Right Cessation
- 2005-01-28 EP EP05702040A patent/EP1713813B1/en not_active Expired - Lifetime
- 2005-01-28 WO PCT/GB2005/000288 patent/WO2005073237A2/en not_active Ceased
-
2006
- 2006-06-27 ZA ZA200605307A patent/ZA200605307B/en unknown
- 2006-07-13 IL IL176863A patent/IL176863A0/en unknown
- 2006-07-26 CO CO06073254A patent/CO5700743A2/es not_active Application Discontinuation
- 2006-07-28 KR KR1020067015417A patent/KR101210361B1/ko not_active Expired - Fee Related
- 2006-07-28 EC EC2006006735A patent/ECSP066735A/es unknown
- 2006-08-22 MA MA29278A patent/MA28364A1/fr unknown
- 2006-08-29 NO NO20063843A patent/NO20063843L/no not_active Application Discontinuation
-
2007
- 2007-07-13 US US11/827,570 patent/US8236958B2/en active Active
-
2008
- 2008-12-10 CY CY20081101439T patent/CY1108647T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050769A1 (es) | Formas polimorficas de un agonista de gabaa | |
| PE20080266A1 (es) | 4-amino-pirido[3,2-e]pirazinas, su uso como inhibidores de fosfodiesterasa 10 y procesos para su preparacion | |
| PE20080711A1 (es) | Pirido[3,2-e] pirazinas, su uso como inhibidores de la fosfodiesterasa 10 y procesos para preparlas | |
| PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
| ES2718930T3 (es) | Método de preparación de calcobutrol | |
| PE20071238A1 (es) | Proceso para la preparacion de heterociclos hidroxi substituidos | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| TW200740805A (en) | Novel compounds | |
| ECSP099708A (es) | Nuevos métodos | |
| EP2213674A4 (en) | CLEANING PROCEDURE FOR PEMETREXED SALTS, SODIUM SALT AND SODIUM SALT | |
| CU20220003A7 (es) | Derivados de imidazo[4,5-c]piridina como agonistas de receptores tipo toll | |
| PA8652101A1 (es) | Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados | |
| AR047739A1 (es) | Polimorfos cristalinos de un ligando receptor de cxc-quimiocina | |
| PE20081556A1 (es) | Formas cristalinas de glyt1 | |
| AR024494A1 (es) | Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos | |
| AR079575A1 (es) | Procedimiento para la purificacion de pirazoles | |
| RU2561281C1 (ru) | Антибактериальные средства на основе четвертичных аммониевых солей | |
| ECSP088319A (es) | Síntesis de inhibidores de renina que involucra una reacción de cicloadición | |
| CL2008002777A1 (es) | Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario. | |
| ES2207194T3 (es) | Acilbenzoxazinas para potenciar la(s) respuesta(s) sinaptica(s). | |
| UY29668A1 (es) | Nuevos derivados de heptaazafenaleno, procedimientos para su obtencinn, ase como utilizacinn de estos como agentes protectores contra la radicacinn uv.- | |
| WO2021086966A1 (en) | Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| AR057291A1 (es) | Proceso para la preparacion de acidos bisfosfonicos geminales y las sales y/o hidratos farmaceuticamente aceptables de los mismos, una composicion farmaceutica que los contiene y el uso de esta en el tratamiento de la osteoporosis | |
| UY31404A1 (es) | "proceso mejorado para preparar 2-(fenilo sustituido)-2-hidroxi-etil carbamatos" | |
| UY30798A1 (es) | Sales de timo depresores farmacéuticamente aceptables y procesos para su manufactura |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |